Prophase Labs (PRPH) Investor presentation summary

Strategic initiatives and business verticals

• Pursuing over $50 million in net near-term cash recovery from COVID-19 receivables through Crown Medical Collections, with litigation against insurance companies underway and anticipated settlements in the coming months.

• BE-Smart esophageal cancer diagnostic test targets a $7–14 billion market, validated by a pivotal study and supported by a new U.S. patent for risk assessment in esophageal adenocarcinoma.

• Nebula Genomics offers a 16-petabyte DNA dataset spanning 130 countries, with a scalable, subscription-based revenue model and proprietary bioinformatics.

• Launched DNA Complete and DNA Expand, providing direct-to-consumer whole genome sequencing and advanced ancestry analysis, with a focus on privacy and data security.

• Equivir, a clinically studied dietary supplement, is in development as a potential lead product for the supplements division.

BE-Smart commercialization and clinical progress

• Active sale and strategic partnership process for BE-Smart is underway, targeting over 70 potential acquirers and partners.

• BE-Smart test is highly sensitive and specific, analyzing existing biopsy blocks from routine endoscopies, and now validated for both pinch and brush biopsies.

• Clinical Science Advisory Board formed, including Dr. Joe Abdo and other key opinion leaders, to support adoption and commercialization.

• Recent validation study demonstrated over 95% technical success rate for BE-Smart in detecting biomarkers for Barrett's esophagus and esophageal adenocarcinoma.

• Planned relaunch of CLIA-certified labs to focus exclusively on esophageal cancer diagnostics using mass spectrometry-based workflows.

Financial restructuring and operational highlights

• Completed restructuring in H2 2025, including the sale of Pharmaloz Manufacturing for $23.6 million, shutdown of the genomics lab, and significant reductions in headcount and IT overhead.

• Crown Medical Collections initiative could recover more than double the current COVID-19 receivables recorded on financial statements.

• Management team has a proven track record in restructuring, growth, and successful exits, including the $50 million sale of Cold-EEZE and the acquisition of Nebula Genomics.

• Exploring strategic alternatives for business units, including potential sale or partnership for BE-Smart.